A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance

Cancer Cell

Volumn 22, Issue 3, 2012, Pages 345-358

  Chauhan, Dharminder ^a   Tian, Ze ^a   Nicholson, Benjamin ^b   Kumar, K G Suresh ^b   Zhou, Bin ^c   Carrasco, Ruben ^a   McDermott, Jeffrey L ^b   Leach, Craig A ^b   Fulcinniti, Mariaterresa ^a   Kodrasov, Matthew P ^b   Weinstock, Joseph ^b   Kingsbury, William D ^b   Hideshima, Teru ^a   Shah, Parantu K ^a   Minvielle, Stephane ^d   Altun, Mikael ^e   Kessler, Benedikt M ^f   Orlowski, Robert ^g   Richardson, Paul ^a   Munshi, Nikhil ^a,h   Anderson, Kenneth C ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b Progenra Inc   (United States)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^d UNIVERSITÉ DE NANTES   (France)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h Veterans Administration Boston Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BORTEZOMIB; CASPASE 3; CD31 ANTIGEN; CYTOTOXIC AGENT; DEXAMETHASONE; LENALIDOMIDE; P 5091; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALIA;

EID: 84866021069     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.08.007     Document Type: Article

References (39)

1. Adams J. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 2004, 4:349-360.
2. Anderson K.C. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp. Hematol. 2007, 35(4, Suppl 1):155-162.
3. Borodovsky A., Ovaa H., Kolli N., Gan-Erdene T., Wilkinson K.D., Ploegh H.L., Kessler B.M. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol. 2002, 9:1149-1159.
4. Chauhan D., Catley L., Li G., Podar K., Hideshima T., Velankar M., Mitsiades C., Mitsiades N., Yasui H., Letai A., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005, 8:407-419.
5. Chauhan D., Hideshima T., Anderson K.C. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu. Rev. Pharmacol. Toxicol. 2005, 45:465-476.
6. Chauhan D., Singh A., Brahmandam M., Podar K., Hideshima T., Richardson P., Munshi N., Palladino M.A., Anderson K.C. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008, 111:1654-1664.
7. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
8. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat. Rev. Mol. Cell Biol. 2005, 6:79-87.
9. Cummins J.M., Rago C., Kohli M., Kinzler K.W., Lengauer C., Vogelstein B. Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 2004, 428. 1 p following 486.
10. Enge M., Bao W., Hedström E., Jackson S.P., Moumen A., Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009, 15:171-183.
11. Everett R.D., Meredith M., Orr A., Cross A., Kathoria M., Parkinson J. A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J. 1997, 16:1519-1530.
12. Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 2000, 275:8945-8951.
13. Hjerpe R., Aillet F., Lopitz-Otsoa F., Lang V., England P., Rodriguez M.S. Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. EMBO Rep. 2009, 10:1250-1258.
14. Hershko A. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ. 2005, 12:1191-1197.
15. Hoeller D., Hecker C.M., Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat. Rev. Cancer 2006, 6:776-788.
16. Hu M., Li P., Li M., Li W., Yao T., Wu J.W., Gu W., Cohen R.E., Shi Y. Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 2002, 111:1041-1054.
17. Itahana K., Mao H., Jin A., Itahana Y., Clegg H.V., Lindström M.S., Bhat K.P., Godfrey V.L., Evan G.I., Zhang Y. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 2007, 12:355-366.
18. Kon N., Kobayashi Y., Li M., Brooks C.L., Ludwig T., Gu W. Inactivation of HAUSP in vivo modulates p53 function. Oncogene 2010, 29:1270-1279.
19. Kon N., Zhong J., Kobayashi Y., Li M., Szabolcs M., Ludwig T., Canoll P.D., Gu W. Roles of HAUSP-mediated p53 regulation in central nervous system development. Cell Death Differ. 2011, 18:1366-1375.
20. Li M., Gu W. A critical role for noncoding 5S rRNA in regulating Mdmx stability. Mol. Cell 2011, 43:1023-1032.
21. Li M., Chen D., Shiloh A., Luo J., Nikolaev A.Y., Qin J., Gu W. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002, 416:648-653.
22. Li M., Brooks C.L., Kon N., Gu W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol. Cell 2004, 13:879-886.
23. Lonial S., Waller E.K., Richardson P.G., Jagannath S., Orlowski R.Z., Giver C.R., Jaye D.L., Francis D., Giusti S., Torre C., et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005, 106:3777-3784. SUMMIT/CREST Investigators.
24. Meulmeester E., Maurice M.M., Boutell C., Teunisse A.F., Ovaa H., Abraham T.E., Dirks R.W., Jochemsen A.G. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol. Cell 2005, 18:565-576.
25. Nicholson B., Marblestone J.G., Butt T.R., Mattern M.R. Deubiquitinating enzymes as novel anticancer targets. Future Oncol. 2007, 3:191-199.
26. Nicholson B., Leach C.A., Goldenberg S.J., Francis D.M., Kodrasov M.P., Tian X., Shanks J., Sterner D.E., Bernal A., Mattern M.R., et al. Characterization of ubiquitin and ubiquitin-like-protein isopeptidase activities. Protein Sci. 2008, 17:1035-1043.
27. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V., Srkalovic G., Alsina M., Alexanian R., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348:2609-2617.
28. Sheaff R.J., Singer J.D., Swanger J., Smitherman M., Roberts J.M., Clurman B.E. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol. Cell 2000, 5:403-410.
29. Song M.S., Salmena L., Carracedo A., Egia A., Lo-Coco F., Teruya-Feldstein J., Pandolfi P.P. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 2008, 455:813-817.
30. Stommel J.M., Wahl G.M. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 2004, 23:1547-1556.
31. Tian X., Isamiddinova N.S., Peroutka R.J., Goldenberg S.J., Mattern M.R., Nicholson B., Leach C. Characterization of selective ubiquitin and ubiquitin-like protease inhibitors using a fluorescence-based multiplex assay format. Assay Drug Dev. Technol. 2011, 9:165-173.
32. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
33. Wang H., Nan L., Yu D., Agrawal S., Zhang R. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin. Cancer Res. 2001, 7:3613-3624.
34. Wang H., Nan L., Yu D., Lindsey J.R., Agrawal S., Zhang R. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms. Mol. Med. 2002, 8:185-199.
35. Wu Q., Kirschmeier P., Hockenberry T., Yang T.Y., Brassard D.L., Wang L., McClanahan T., Black S., Rizzi G., Musco M.L., et al. Transcriptional regulation during p21WAF1/CIP1-induced apoptosis in human ovarian cancer cells. J. Biol. Chem. 2002, 277:36329-36337.
36. Xu H., Zhang Z., Li M., Zhang R. MDM2 promotes proteasomal degradation of p21Waf1 via a conformation change. J. Biol. Chem. 2010, 285:18407-18414.
37. Zhang Z., Li M., Wang H., Agrawal S., Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc. Natl. Acad. Sci. USA 2003, 100:11636-11641.
38. Zhang Z., Wang H., Li M., Agrawal S., Chen X., Zhang R. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J. Biol. Chem. 2004, 279:16000-16006.
39. Zhao R., Yeung S.C., Chen J., Iwakuma T., Su C.H., Chen B., Qu C., Zhang F., Chen Y.T., Lin Y.L., et al. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J. Clin. Invest. 2011, 121:851-865.